Royalty-free license means companies in 105 countries can sublicense the formulation for antiviral pill molnupiravir and start making it
Adding Interferon Beta-1a to Remdesivir No Better for COVID-19
For hospitalized adults with COVID-19, time to recovery did not differ with interferon beta-1a plus remdesivir versus remdesivir alone
Poisoning Related to Ivermectin Exposure for COVID-19 Described
In August 2021, 21 calls were received by Oregon Poison Center; six people were hospitalized for toxic effects resulting from use
Merck Asks FDA to Approve First COVID-19 Antiviral Pill
Molnupiravir could be major advance because it reaches more high-risk patients than the monoclonal antibody treatments now being used
Infection Risk Does Not Seem to Differ Among Biologics for Psoriasis
Differential risk for serious infection or respiratory tract infection, including SARS-CoV-2, not seen among biologics used to treat psoriasis
Glucose-Regulating Drugs Aid COVID-19 Outcomes in Patients With Diabetes
Findings include GLP-1R agonists and pioglitazone use, with drop in hospital admissions
REGEN-COV Reduces Risk for COVID-19 Hospitalization, Death
Among outpatients with COVID-19 at high risk, risk for hospitalization, death reduced with monoclonal antibody combo versus placebo
Merck to Ask FDA for Emergency Approval of Its New Antiviral Pill for COVID-19
New medication is just one of several antiviral pills now being tested in studies
WHO Issues Guidance for Use of Casirivimab-Imdevimab in COVID-19
Combo conditionally recommended for patients with nonsevere disease at risk for severe disease, seronegative patients with severe infection
Uptake Low for Monoclonal Antibodies for COVID-19
Use peaked in January and declined in early 2021, at the time of the vaccine rollout